Fiege Healthcare Logistics Gmbh Pharmaceutical Import Profile — Germany (DGFT 2022–2026)

Name: Fiege Healthcare Logistics Gmbh Pharmaceutical Import Records from India — 2 Products, $2.8M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Fiege Healthcare Logistics Gmbh — Pharmaceutical Importer Profile (2026) | 2 Products, $2.8M Trade | TransData Nexus

Fiege Healthcare Logistics Gmbh

Pharmaceutical Importer · Germany · Advanced Diabetes Medications Focus · $2.8M Total Trade · DGFT Verified

Fiege Healthcare Logistics Gmbh is a pharmaceutical importer based in Germany with a total trade value of $2.8M across 2 products in 2 therapeutic categories. Based on 80 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Fiege Healthcare Logistics Gmbh sources from 9 verified Indian suppliers, with Msn Laboratories Private Limited accounting for 38.3% of imports.

Fiege Healthcare Logistics Gmbh — Import Portfolio & Supplier Network

Fiege Healthcare Logistics Gmbh import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Fiege Healthcare Logistics Gmbh?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Msn Laboratories Private Limited	$7.6M	255	38.3%
Alembic Pharmaceuticals Limited	$4.7M	220	23.6%
Lupin Limited	$2.0M

What Formulations Does Fiege Healthcare Logistics Gmbh Import?

Formulation	Value	Ships
Gliclazide sandoz 30MG 30 nl gliclazide modified release tablets others-medicine put up for retail	$258.1K	8
Gliclazide sandoz 30MG 30 nl gliclazidemodified release tablets others-medicine put up for retail	$204.2K	12
Gliclazide mr TAB 60MG 30 sandoz francegliclazide mr tablets others-medicine put up for retail	$180.3K	5
Pharma drugs and medi exemestan sandoz	$153.6K	4
Alnodine 180MG tablets (fexofenadine)	$151.6K	7
Gliclazide mr TAB 60MG 90 sandoz francegliclazide modified release tablets others-medicine put up for retail	$151.1K	6
Dabigatran sdz 150MG 60hgc bonl batch	$150.0K	3
Pharmaceutical drugs and medicine	$128.3K	5
Pharma drugs and medi exemestan 25MG	$119.8K	3
Dabigatran etexilat 1a 110MG 60hgc ud atbatch no	$119.8K	3
Ph.dru. & med.: exemestan sandoz 25MG tablets (exemestane tablets 25MG Each tablet cont: exemestane 25MG) [3885x6x15t]	$116.6K	3
Airflusan sprayhaler 25/125mcgsalmeterol 25mcg/fluticasone propionate 125 MCG [pac size:1x120	$113.8K	3
Dabigatran sdz 150MG 180hgc ud be	$111.0K	4
Bupropion hcl sandoz 150 MG 90's nl (18921.000x 90 tabs = 1702890	$109.5K	3
Ph.dru. & med.: exemestan 25MG tablets	$100.2K	4

Fiege Healthcare Logistics Gmbh imports 622 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Gliclazide	Advanced Diabetes Medications	$2.2M	61	0.7%	10
2	Exemestane	Advanced Oncology	$604.5K	19	4.2%	4

Fiege Healthcare Logistics Gmbh imports 2 pharmaceutical products across 2 categories into Germany totaling $2.8M.

Fiege Healthcare Logistics Gmbh — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Fiege Healthcare Logistics GmbH is a specialized logistics service provider based in Greven, Germany, focusing on the healthcare sector. As part of the FIEGE Group, a fifth-generation family-run business established in 1873, Fiege Healthcare Logistics GmbH leverages over 25 years of experience in pharmaceutical logistics. The company offers comprehensive services, including temperature-controlled warehousing, international distribution, and flexible supply chain solutions, all in strict compliance with Good Distribution Practice (GDP) and Good Manufacturing Practice (GMP) standards.

Fiege Healthcare Logistics GmbH operates as a third-party logistics (3PL) provider, managing the storage, handling, and distribution of pharmaceutical products for various clients. Its role in Germany's pharmaceutical distribution network is pivotal, ensuring the efficient and compliant movement of medical products from manufacturers to end-users, including hospitals, pharmacies, and clinics. The company's expertise in managing complex logistics requirements, such as temperature-sensitive shipments and regulatory compliance, positions it as a key player in the healthcare logistics sector.

2Distribution Network

Fiege Healthcare Logistics GmbH operates an extensive distribution network across Germany, with its headquarters located in Greven, North Rhine-Westphalia. The company manages multiple facilities, including a significant logistics center in Münster, which is ISO 13485 and GDP certified, ensuring compliance with international quality standards for medical products. This facility handles a broad range of medical products, including pharmaceuticals, medical instruments, and consumables, serving over 50 hospitals and 600 doctor's offices.

Fiege Healthcare Logistics GmbH's logistics capabilities encompass temperature-controlled warehousing, international distribution, and flexible supply chain solutions. The company ensures compliance with GDP and GMP standards, maintaining the integrity and safety of pharmaceutical products throughout the supply chain. Its geographic coverage extends beyond Germany, with operations in other European countries, facilitating efficient distribution of healthcare products across the continent.

3Industry Role

Fiege Healthcare Logistics GmbH functions primarily as a third-party logistics (3PL) provider within Germany's pharmaceutical supply chain. The company specializes in the storage, handling, and distribution of pharmaceutical products, ensuring compliance with stringent regulatory standards such as GDP and GMP. By managing complex logistics operations, Fiege Healthcare Logistics GmbH plays a crucial role in maintaining the efficiency and reliability of the pharmaceutical supply chain, facilitating the timely delivery of medical products to healthcare providers and patients.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Fiege Healthcare Logistics Gmbh

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Fiege Healthcare Logistics GmbH's sourcing strategy reveals a significant concentration in its supplier base, with nine verified Indian suppliers accounting for the majority of its pharmaceutical imports. The top five suppliers—MSN Laboratories Private Limited, Alembic Pharmaceuticals Limited, Lupin Limited, Intas Pharmaceuticals Limited, and Cipla Limited—collectively represent 81.7% of the total import value from India.

This concentration indicates a strategic choice to partner with established and reputable suppliers, ensuring consistent product quality and reliability. The substantial volume of imports from these suppliers suggests stable and long-term relationships, which are essential for maintaining the integrity of the supply chain. However, such dependency on a limited number of suppliers may pose risks related to supply chain disruptions, pricing fluctuations, and potential regulatory changes affecting these suppliers.

The shipment data, with 80 total shipments from India, reflects a steady and ongoing procurement process. The high number of shipments from the top suppliers indicates a well-established and efficient logistics operation, capable of managing complex international supply chains. Nonetheless, the concentration of sourcing from a few suppliers necessitates continuous monitoring and risk management strategies to mitigate potential vulnerabilities.

2Supply Chain Resilience

Importing Pharmaceuticals into Germany — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Germany

1Regulatory Authority & Framework

In Germany, the primary regulatory authority overseeing pharmaceutical imports is the Federal Institute for Drugs and Medical Devices (BfArM). BfArM is responsible for ensuring the safety, efficacy, and quality of medicinal products, including those imported from non-EU countries. Key legislation governing pharmaceutical imports includes the German Medicines Act (AMG), which outlines requirements for marketing authorization, importation, and distribution of medicinal products.

The marketing authorization pathway for Indian generics involves obtaining approval from BfArM, which requires comprehensive documentation demonstrating the product's quality, safety, and efficacy. This process includes submitting a Common Technical Document (CTD) comprising modules on administrative information, quality, non-clinical and clinical data, and labeling. Additionally, compliance with EU regulations, such as the EU GMP guidelines, is mandatory for all pharmaceutical products imported into Germany.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in Germany are stringent. Importers must hold a wholesale distribution authorization in accordance with Section 52a of the German Medicines Act (AMG), which permits the wholesale distribution of medicinal products. This authorization ensures that importers adhere to the necessary standards for storage, handling, and distribution of pharmaceuticals.

Fiege Healthcare Logistics Gmbh — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Fiege Healthcare Logistics GmbH's product category focus on advanced diabetes medications and advanced oncology reflects a strategic alignment with prevalent health concerns in Germany. Diabetes and cancer are among the most common and costly health conditions, driving significant demand for effective treatments. By concentrating on these therapeutic areas, Fiege Healthcare Logistics GmbH addresses critical patient needs and positions itself as a key player in delivering essential medications to the German market.

The market demand for these imports is influenced by factors such as the aging population, increasing prevalence of chronic diseases, and advancements in medical research leading to new treatment options. Fiege Healthcare Logistics GmbH's

TransData Nexus Research · DGFT trade data analysisMar 2026

Frequently Asked Questions — Fiege Healthcare Logistics Gmbh

What products does Fiege Healthcare Logistics Gmbh import from India?

Fiege Healthcare Logistics Gmbh imports 2 pharmaceutical products across 2 categories. Top imports: Gliclazide ($2.2M), Exemestane ($604.5K).

Who supplies pharmaceuticals to Fiege Healthcare Logistics Gmbh from India?

Fiege Healthcare Logistics Gmbh sources from 9 verified Indian suppliers. The primary supplier is Msn Laboratories Private Limited (38.3% of imports, $7.6M).

What is Fiege Healthcare Logistics Gmbh's total pharmaceutical import value?

Fiege Healthcare Logistics Gmbh's total pharmaceutical import value from India is $2.8M, based on 80 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Fiege Healthcare Logistics Gmbh focus on?

Fiege Healthcare Logistics Gmbh imports across 2 categories. The largest: Advanced Diabetes Medications (78.5%), Advanced Oncology (21.5%).

Get Full Fiege Healthcare Logistics Gmbh Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.